《中共中央关于制定国民经济和社会发展第十五个五年规划的建议》指出，"推进中医药传承创新，促 进中西医结合"。 近日，上海交通大学医学院附属瑞金医院与上海传承导引医学研究所联合完成一项临床研究，将列入国 家级非物质文化遗产代表性项目名录中的"中医诊疗法（古本易筋经十二势导引法）"，与帕金森脑深部 电刺激（DBS）术后康复相结合，在帕金森构音障碍的治疗上取得新突破。研究成果发表于国际期刊 《中枢神经系统神经科学与治疗学》。 这一"融合古今"的医学探索，为帕金森病患者带来了康复新路径，也为中西医融合治疗神经退行性疾病 提供了新范式。 当中医导引法遇上现代医学 帕金森病是一种神经系统退行性疾病，主要症状为静止性震颤、动作迟缓及减少、肌张力增高、姿势异 常等。《中国帕金森病治疗指南（第四版）》显示，我国65岁以上老年人群中，帕金森病患病率为 1.7%。 说话含糊不清、喝水频繁呛咳、进食困难……这是许多帕金森病患者的"无声困境"。在上海交通大学医 学院附属瑞金医院，神经外科主任医师李殿友见到过许多有着类似症状的患者。作为神经系统退行性疾 病，帕金森病尚无法根治，其引发的构音与吞咽障碍，严重影响着患者的生活质量和生命安全。 ...

Core Viewpoint - The article highlights the innovative leadership of Gu Qiang, the director of Beijing Puren Hospital, in advancing healthcare services and reforming the medical system in Beijing, emphasizing the importance of quality healthcare and community service [3][4][5][6]. Group 1: Hospital Development and Management - Gu Qiang has led the establishment of Beijing Puren Medical Group, implementing the "Five Unchanged, Five Unified" management principle to enhance operational efficiency across various healthcare facilities [3]. - The hospital has seen a 22% increase in outpatient visits at the Dongcheng District Maternal and Child Health Hospital within two years due to performance reforms that link patient satisfaction to staff promotions [3]. - A remote medical platform has been developed to allow real-time transmission of X-ray images from community health service centers to the hospital's imaging center, facilitating expert consultations [3]. Group 2: Quality of Care and Medical Innovation - Gu Qiang has prioritized academic development by designing a "433" discipline framework, focusing on four key specialties, three diagnostic platforms, and three specialty centers to enhance the hospital's reputation [4]. - The hospital achieved high-quality completion of its tertiary comprehensive hospital accreditation, with patient satisfaction rates maintained above 98% [4]. - The implementation of a quality control system covering the entire diagnosis and treatment process has been a key focus, alongside the establishment of a multi-disciplinary consultation model for complex cases [4]. Group 3: Integration of Traditional and Modern Medicine - Gu Qiang has actively promoted the integration of traditional Chinese medicine (TCM) with Western medicine, launching TCM clinics and developing comprehensive treatment plans for chronic disease patients [5]. - Over a thousand community physicians have been trained in TCM techniques, enhancing the capacity for TCM services in grassroots healthcare [5]. - Upgrades to TCM facilities within the medical group have made services like acupuncture and massage more accessible to residents [5]. Group 4: Human-Centered Care and Community Engagement - The hospital has initiated palliative care forums and expanded services for elderly patients, including home care for those with disabilities [6]. - Gu Qiang maintains a hands-on approach, regularly seeing patients and coordinating assistance for those in financial need [6]. - The hospital aims to achieve the status of a tertiary A-level comprehensive hospital by 2025, reflecting its commitment to continuous improvement in healthcare delivery [6].

Core Insights - The recent strategic moves by Guoshengtang, including partnerships with 1doc and AGP, signify a pivotal shift in the internationalization of traditional Chinese medicine (TCM) from merely exporting products to establishing a comprehensive service system [1][4][5] Group 1: Strategic Partnerships - Guoshengtang has completed a significant equity partnership with Singapore's 1doc, where Guoshengtang holds a 70% stake, ensuring deep integration of TCM services within the existing Western medical framework [5][6] - The collaboration with 1doc allows for a comprehensive health management approach, offering patients a combination of TCM and Western medicine within the same healthcare ecosystem [5][6] - The partnership aligns with Singapore's government initiatives promoting the integration of TCM into mainstream healthcare, particularly through the upcoming "Traditional Chinese Medicine Integration Sandbox" plan [5][6] Group 2: Technological Innovations - The launch of the "National Medicine AI Avatar" aims to standardize and replicate TCM practices, providing a platform for overseas practitioners to enhance their clinical skills [6][9] - This AI system is designed to assist local TCM practitioners in formulating precise treatment plans, thereby establishing high-quality TCM service standards in international markets [9][10] - The integration of AI technology in TCM practices has garnered recognition from Singapore's government, indicating strong support for innovative approaches in traditional medicine [9][10] Group 3: Capital Support - Guoshengtang's strategic partnership with AGP will provide direct investment to support its internationalization strategy and AI technology development [7][10] - AGP's investment not only offers financial backing but also access to a network of healthcare resources and insights into international market regulations [10] - The capital infusion reflects confidence in Guoshengtang's ability to address core challenges in TCM's international expansion through a systematic approach combining AI and operational integration [10]

Core Viewpoint - The strategic partnership between Guoshengtang and Singapore's 1doc aims to integrate Traditional Chinese Medicine (TCM) into the mainstream medical system in Singapore, marking a significant milestone for the internationalization of TCM [1][4]. Group 1: Partnership Details - Guoshengtang and 1doc will systematically introduce TCM services in Western medical family clinics in Singapore, providing a collaborative healthcare experience that covers clinical diagnosis, daily health care, and community health [1][3]. - The partnership will involve a shareholding structure where Guoshengtang holds 70% and 1doc holds 30%, ensuring deep integration and professional operation of TCM services within Western medical settings [3][4]. - Patients will benefit from a comprehensive healthcare management approach that includes prevention, diagnosis, and rehabilitation, facilitated by TCM practitioners who can prescribe necessary tests to enhance diagnostic accuracy [3][4]. Group 2: Policy and Market Context - The Singapore government has been actively promoting the integration of TCM and Western medicine, exemplified by the "TCM Integration Sandbox Program" set to launch in 2025, which will test and evaluate TCM treatment plans in public healthcare institutions [4][5]. - 1doc, a subsidiary of IHG, operates a network of clinics in Singapore and has served over 79,000 patients, providing a strong local medical network and digital technology support for the implementation of TCM [4][5]. - Guoshengtang, as China's first publicly listed TCM chain, has established over 80 medical institutions in China and Singapore, serving more than 20 million customers and accumulating extensive clinical data to support the efficacy and safety of TCM [4][5]. Group 3: Future Prospects - The collaboration aims to create a "New TCM" service model in Singapore, exploring more partnership models to build a new ecosystem of collaborative diagnosis and treatment [5]. - The innovative policies and market openness in Singapore provide a high-standard international testing ground for Guoshengtang, with potential for replicating successful models in Southeast Asia and globally [5].

Core Viewpoint - The strategic partnership between Guoshengtang and Singapore's 1doc marks a significant milestone in integrating Traditional Chinese Medicine (TCM) into Singapore's mainstream healthcare system, promoting the internationalization of TCM [1][4]. Group 1: Partnership Details - Guoshengtang and 1doc will systematically introduce TCM services in Western medical family clinics in Singapore, providing a collaborative healthcare experience that covers clinical diagnosis, daily health care, and community health [1][3]. - The partnership structure involves Guoshengtang holding 70% and 1doc holding 30% of the TCM operations, ensuring deep integration and professional management of TCM services within Western medical settings [3][4]. - Patients will benefit from a comprehensive health management approach that includes prevention, diagnosis, and rehabilitation, facilitated by TCM practitioners who can prescribe necessary tests to enhance diagnostic accuracy [3][4]. Group 2: Policy and Market Context - The Singapore government has been actively promoting the integration of TCM and Western medicine, exemplified by the "TCM Integration Sandbox Program" set to launch in 2025, which will test and evaluate TCM treatment plans in public healthcare institutions [4][5]. - 1doc, a subsidiary of IHG, operates a robust network of clinics in Singapore, leveraging advanced technologies to support personalized and preventive healthcare, which will aid in the implementation of TCM services [4][5]. - Guoshengtang, as China's first publicly listed TCM chain, has established over 80 medical institutions in China and Singapore, serving more than 20 million patients, and has accumulated extensive clinical data to support the efficacy and safety of TCM [4][5]. Group 3: Future Prospects - The collaboration aims to create a "New TCM" service model in Singapore, exploring more partnership models to build a new ecosystem of collaborative diagnosis and treatment [5]. - Singapore's innovative policies and market openness provide a high-standard international testing ground for Guoshengtang, with potential for replicating successful models in Southeast Asia and globally [5].

Core Viewpoint - The strategic partnership between Gu Shengtang and 1doc marks a significant milestone for the integration of Traditional Chinese Medicine (TCM) into Singapore's mainstream healthcare system, promoting the internationalization of TCM [1][4]. Group 1: Partnership Details - Gu Shengtang and 1doc will systematically introduce TCM services in Western medical family clinics in Singapore, providing a collaborative healthcare experience that covers clinical diagnosis, daily health care, and community health [1][3]. - The partnership structure involves Gu Shengtang holding 70% of the shares and fully managing operations, while 1doc holds 30%, ensuring deep integration and professional operation of TCM services within Western medical settings [3][4]. - Patients will benefit from a comprehensive health management approach that includes prevention, diagnosis, and rehabilitation, facilitated by TCM practitioners who can prescribe necessary tests to enhance diagnostic accuracy [3][4]. Group 2: Supportive Environment - The Singaporean government actively promotes the integration of TCM and Western medicine, exemplified by the "TCM Integration Sandbox Program" set to launch in 2025, which will test and evaluate TCM treatment plans in public healthcare institutions [4]. - 1doc, a subsidiary of IHG, operates a robust network of clinics in Singapore, leveraging advanced digital technologies to support personalized and preventive healthcare, which will bolster the implementation of TCM [4][5]. - Gu Shengtang, as the first publicly listed TCM chain in China, has established over 80 medical institutions and served more than 20 million clients, providing a strong evidence base for the efficacy and safety of TCM [4][5]. Group 3: Future Prospects - The collaboration aims to create a "New TCM" service model in Singapore, representing Gu Shengtang's exploration of digital integration into international healthcare systems [5]. - Future plans include exploring more partnership models to build a collaborative healthcare ecosystem, promoting standardized and scalable development of TCM in international markets [5]. - Singapore's innovative policies and market openness provide a high-standard testing ground for Gu Shengtang, with potential for replicating successful models across Southeast Asia and globally [5].

Core Insights - The establishment of the "Capital Famous Traditional Chinese Medicine Dong Rui AI Lung Nodule Diagnosis and Treatment Platform" marks a significant milestone for Zibo in integrating renowned medical expertise with artificial intelligence in respiratory disease prevention and treatment [1][3] - This initiative aims to provide high-quality integrated Chinese and Western medical services to the local population, enhancing the development of traditional Chinese medicine in the region [1][4] Group 1: Platform Launch and Collaboration - The platform's launch follows a partnership agreement signed in March between Zibo Traditional Chinese Medicine Hospital and Beijing Kangyide Integrated Traditional Chinese and Western Medicine Lung Hospital, focusing on innovative treatment models for lung nodules [2][4] - The collaboration is expected to inject new momentum into the development of the hospital's pulmonary medicine discipline [2][3] Group 2: Expert Involvement and Treatment Efficacy - Professor Dong Rui, a leading figure in the field, shared his extensive experience and insights during the unveiling ceremony, highlighting his innovative treatment methods and the clinical success of his team's formulations, which have shown a nodule reduction rate exceeding 39% [3][4] - The platform aims to leverage Professor Dong's expertise to enhance the hospital's capabilities in treating complex cases and fostering high-level talent [4][5] Group 3: Expected Outcomes - The platform is anticipated to provide convenient access to top-tier personalized diagnosis and treatment for lung nodule patients in Zibo and Shandong, significantly reducing their economic and travel burdens [4][5] - It aims to serve as a replicable model for regional integration of Chinese and Western medicine, contributing to the overall improvement of healthcare services in the area [5]

Core Insights - The conference focused on infertility prevention and treatment strategies, emphasizing the innovative application of traditional Chinese medicine (TCM) in reproductive health [1][3][5] Group 1: Conference Overview - The second academic annual meeting and expert tour on infertility and reproductive health was successfully held in Chengdu, organized by the China Medical Education Association and supported by Good Doctor Group and Shenyang Qinggong Pharmaceutical Group [1] - The event gathered renowned experts, scholars, and clinicians in the field of TCM and reproductive health to share authoritative reports, specialized discussions, and practical case studies [1] Group 2: Keynote Highlights - Huang Zhengming, Honorary President of the China Medical Education Association, emphasized the importance of grassroots TCM revitalization and the integration of TCM and Western medicine to address reproductive health challenges [3] - The meeting outlined three strategic actions: strengthening grassroots talent through new expert committee members, honoring frontline doctors as "guardians of health," and promoting specialized courses on infertility to enhance technical capabilities [3] Group 3: Expert Contributions - Huang Zhengming analyzed the dynamic changes in China's fertility rate, discussing the direct impact of contemporary social phenomena on reproductive willingness [5] - Wang Zheng, Vice Chairman of the Health and Medicine Committee of the Chinese People's Political Consultative Conference, highlighted TCM's unique advantages in regulating menstruation and improving endometrial receptivity, advocating for a collaborative approach between TCM and Western medicine [5] Group 4: Initiatives and Future Plans - The Good Doctor Group announced the launch of the "Infertility Reproductive Health Expert Tour" in April 2024, which has already assisted over 5,000 families in overcoming fertility challenges [5] - Aiming for long-term development, the Good Doctor Group plans to establish a "China Reproductive Health Industry Base" centered around Shenyang Qinggong Pharmaceutical, integrating TCM heritage with cutting-edge technology to enhance training and resource allocation for grassroots doctors [5] Group 5: Consensus and Goals - The conference reached a consensus on enhancing reproductive health service levels, contributing to national population strategies, and supporting the "Healthy China 2030" initiative [7]